Nutra Pharma Corp. is a biotechnology company that is developing proprietary therapeutic protein products for the prevention and treatment of viral and neurological diseases. These diseases the company is working on include: multiple sclerosis (MS), HIV, adrenomyeloneuropathy (AMN) and also pain treatment.
The company announced today that it has hired David Isserman to serve as its chief marketing officer. Mr. Isserman, a longtime consultant to the company, will be responsible for overseeing the company’s corporate communications and investor relations. In addition, he will work directly with Nutra Pharma licensees to coordinate ongoing marketing and outreach initiatives for the company’s drug pipeline, including its recently launched pain relievers, Cobroxin and Nyloxin.
Prior to joining Nutra Pharma, Mr. Isserman served as president of Isserman Consulting, a boutique marketing communications consultancy that advised early-stage biotechnology, consumer products and technology companies. He was also a co-founder of RareShare, a website developed to connect patients and healthcare providers affected by rare medical disorders.
Nutra Pharma believes Mr. Isserman’s extensive knowledge and experience in marketing communications and his work within the biotechnology industry will serve as a tremendous asset for the company. This will be especially true as the company tries to build their presence within the investment and scientific communities regarding its important work developing novel treatments for neurologic and autoimmune disorders. In addition, Nutra Pharma is hoping that Mr. Isserman will be able to extend the global awareness and reach of their drug brands.